Key result
The addition of multiple biomarkers, including C-reactive protein, adds only moderately to the overall prediction of cardiovascular risk based on conventional risk factors.
Why the study?
Does C-reactive protein improve risk prediction in patients with acute coronary syndrome compared to conventional risk scores alone?
Does C-reactive protein improve risk prediction in patients with acute coronary syndrome compared to conventional risk scores alone?
No takes yet. Share an insight, caveat, or question.
C-reactive protein and other biomarkers appear to add only moderate incremental prognostic value beyond established clinical risk scores in ACS patients.
J. C. Kaski (2009) conducted an editorial in Acute coronary syndrome. C-reactive protein was evaluated. The addition of multiple biomarkers, including C-reactive protein, adds only moderately to the overall prediction of cardiovascular risk based on conventional risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: